This task order is for the development of a protocol, clinical trial implementation, closeout and analysis of a phase 2 clinical trial to evaluate the efficacy of rmenb+OMV NZ (bexsero, GSK) in…
Active Awarded Last action
- Contract number
- 75N93019F00131
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,820,523
Award facts
- Contract value 72% obligated
-
- $8,820,522.74 Current, with exercised options
- $12,237,078.74 Potential, with all options
- Completion date 99% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Birmingham, AL 35294, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $318,032 | |
| Supplemental Agreement for work within scope | $1,046,990 | |
| Supplemental Agreement for work within scope | $76,652 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $771,792 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $3,074,366 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $3,532,691 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Alabama at Birmingham a delivery order valued at $12.24 million to conduct a Phase 2 clinical trial evaluating the efficacy of Bexsero (rMenB+OMV NZ), a meningococcal vaccine manufactured by GSK, in preventing Neisseria gonorrhoeae infection. The task order encompasses protocol development, clinical trial implementation, trial closeout, and data analysis, with performance to occur in Birmingham, Alabama, and an ultimate completion date of October 31, 2026. The contract was awarded on August 23, 2019, under a cost-plus-no-fee pricing structure with no set-aside designation.
This delivery order leverages UAB's substantial expertise in clinical research and infectious disease investigations, supported by the institution's extensive portfolio of NIAID-funded grants spanning HIV prevention, influenza research, and immunological studies. As a comprehensive academic medical center with demonstrated capabilities in biomedical research and clinical trial integration, UAB is well-positioned to execute this vaccine efficacy trial, which addresses an important public health need by investigating an off-label application of an approved meningococcal vaccine for gonorrhea prevention.
Description
This task order is for the development of a protocol, clinical trial implementation, closeout and analysis of a phase 2 clinical trial to evaluate the efficacy of rmenb+OMV NZ (bexsero, GSK) in preventing n. Gonorrhoeae infection.
Quick answers
Who was awarded contract 75N93019F00131?
75N93019F00131 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 23, 2019.
How much is contract 75N93019F00131 worth?
The government has obligated $8,820,523 on 75N93019F00131. Its potential value, with all options, is $12,237,079.
Is contract 75N93019F00131 an order under another contract?
Yes. 75N93019F00131 is a delivery order under HHSN272201300012I, an indefinite delivery contract.
Was contract 75N93019F00131 competed?
The extent of competition for 75N93019F00131 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award